SEATTLE, Wa., January 6, 2017 - Adaptive Biotechnologies, the leader in combining next-generation sequencing (NGS) and expert bioinformatics to profile T- and B-cell receptors of the adaptive immune system, announces it has entered into an agreement with Amgen to further develop and commercialize Adaptive’s NGS-based clonoSEQ Assay to assess minimal residual disease (MRD) in patients with Acute Lymphoblastic Leukemia (ALL).
BREAKING NEWS FROM ADAPTIVE
SOUTH SAN FRANCISCO, Calif. – Sequenta, Inc. today announced that the DFCI/ALL Consortium will utilize the ClonoSIGHT™ test, the first sequencing-based test for minimal residual disease (MRD) in lymphoid cancers, for clinical care of children with ALL.
Julie Rubinstein, Adaptive’s SVP of Business Development, will speak at Bloomberg’s State of Health Care 2014 Conference in New York City. She will participate on an expert panel entitled Innovation in Healthcare, which will feature the growth and promise of cancer immunotherapy.
SEATTLE, WA, January 13, 2014 – Adaptive Biotechnologies announced today a biomarker discovery agreement facilitated by the Johnson & Johnson Innovation Center in California. Under the agreement, Adaptive will use its patented immune profiling assay, immunoSEQTM, to enable an in-depth characterization of the immune response to diseases being studied and select immunology and oncology drugs being developed by Janssen Research & Development, LLC (Janssen). The exploration of immune response may identify patient populations more likely to respond to targeted therapies based on their immune status.
SEATTLE, WA, January 13, 2014 – Adaptive Biotechnologies announced today two high profile additions to its Board of Directors to strengthen its healthcare distribution system and software expertise and to add the financial experience necessary for commercialization.
Adaptive announced today that Chad Robins, Founder and Chief Executive Officer, is scheduled to present a company overview at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 15th, 2014 at 2:00pm PST.
Ultra-sensitive sequencing-based minimal residual disease test provides enhanced prognostic value over current methods and reveals new disease insights
Ultra-sensitive sequencing-based detection of minimal residual disease may also allow enhanced monitoring in other types of lymphoma
CBS News just published a story highlighting the promise of Adaptive’s QuanTILfy test that is being tested in many solid tumors for the prognosis, diagnosis, and monitoring of cancer patients. The article is based on a study published yesterday in Science Translational Medicine demonstrating that QuanTILfy may help predict survival in ovarian cancer patients.
First sequencing-based minimal residual disease test for lymphoid cancers already validated in acute lymphoblastic leukemia, chronic lymphocytic leukemia and mantle cell lymphoma
Adaptive and its collaborators will present data demonstrating how immunosequencing can inform survival in patients with blood cancers at the American Society of Hematology (ASH) meeting from December 7-10, 2013.